One U.S. company working on a COVID-19 vaccine has released a suspected price range per dose, according to the company.
Moderna stated that it will price it’s vaccines around $35 if the vaccine makes it through remaining trials and to market.
“We are pleased to have started the Phase 3 COVE study,” said Stephane Bancel, CEO at Moderna, in late July when the drug entered trials. “We are grateful to the efforts of so many inside and outside the company to get us to this important milestone. We are indebted to the participants and investigators who now begin the work of the COVE study itself. We look forward to this trial demonstrating the potential of our vaccine to prevent COVID-19, so that we can defeat this pandemic.”
They are looking to complete enrollment for phase 3 trials before October. This trial includes 30,000 volunteers for the study.
U.S. companies Norivax and Pfizer also have vaccine candidates in the race.
In June, Gilead Sciences revealed its Remdesivir drug would cost more than $500 per vial for people with private health insurance. Remdesivir is used to treat people already infected with COVID-19 and studies have shown that it improved patient recovery times